Is immunotherapy effective for cardia cancer?
Oct 30, 2024
Source: Cainiu Health
Dr. Qi Zhirong
Introduction
Immunotherapy works by activating the body's immune system to recognize and attack cancer cells, thereby inhibiting their growth and spread. The effectiveness of immunotherapy for gastric cardia cancer depends on the stage of treatment and should be evaluated accordingly. To achieve the best therapeutic outcomes, patients should actively communicate with their doctors, follow medical advice, undergo regular follow-up examinations, and maintain healthy lifestyle habits, such as eating a balanced diet and engaging in moderate exercise.
In general, immunotherapy works by activating the body's immune system to recognize and attack cancer cells, thereby inhibiting their growth and spread. The effectiveness of immunotherapy for贲门癌 (gastric cardia cancer) depends on the stage at which treatment is administered. Immunotherapy tends to be more effective when given in the early stages of the disease, whereas its efficacy may be less satisfactory in advanced stages. If any discomfort occurs, patients should seek medical attention promptly. A detailed analysis is as follows:
In the early stages of gastric cardia cancer, cancer cells are typically localized and have not yet undergone widespread metastasis or dissemination. At this point, the immune system has not been fully suppressed and still retains strong anti-tumor capabilities. Therefore, administering immunotherapy early can more effectively activate and enhance the patient’s own immune system, enabling it to better recognize and destroy cancer cells, thus helping control disease progression and prolong survival. Additionally, early intervention helps minimize damage to surrounding tissues caused by tumor invasion, reducing the complexity and risks associated with subsequent treatments.
As gastric cardia cancer progresses, cancer cells gradually spread to other parts of the body, forming extensive metastatic lesions. By this stage, the patient's immune system is often severely compromised and struggles to effectively identify and eliminate cancer cells. Moreover, the condition of late-stage patients is highly variable and frequently complicated by multiple comorbidities and adverse reactions, all of which further diminish the effectiveness of immunotherapy. Consequently, achieving optimal therapeutic outcomes with immunotherapy in advanced stages is challenging, and personalized treatment plans must be carefully developed based on the individual patient’s clinical status and treatment goals.
To achieve the best possible outcomes, patients should actively communicate with their physicians, adhere to medical recommendations, undergo regular follow-up examinations, and maintain healthy lifestyle habits, such as balanced nutrition and moderate physical activity.
